Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.
about
Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor ActivityExpansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive disease.Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective.Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia.Human NK cells activated by EBV(+) lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells.Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells.Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity.Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia.Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia.NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors.HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia.A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies.
P2860
Q26773135-18B36C9E-6348-4AA4-8993-F0CF77250BE9Q34294166-EB01E207-8C5F-40AB-A5F4-BDEDE30A1D18Q35566828-70364DB2-E771-41E6-AB28-1A13682457E3Q35812675-7D58A852-80D8-4696-91A2-DDA4AC5BCDEEQ37362596-43135687-9750-4F16-80C6-FD6AB01F6996Q38285256-1041D8C4-D26D-41A7-87B8-9283FEB16FE5Q38550810-45B31D63-83C5-4510-97B3-A052A3C1C556Q38739764-AB4E41C1-EC97-4E87-9A2D-0D281B365E84Q38878233-9BC8F6DC-F1BB-4E05-BFAC-C42098DB9ADFQ39197427-6D2A54C4-3471-45D7-B09C-64854D029238Q40372471-71AF9284-D181-4EBB-9D7A-EFBFCB8A1C5BQ41625025-9698A00F-3440-429B-B40D-6CE45AA6977EQ48312107-BD229DD2-005B-4E46-89FA-491FE51BCB26Q50502690-E14F04C3-5AE4-4D14-8E74-D4EB2A3AC3CFQ51320808-BE3D91D5-7B71-4AD7-B6F6-F5DDC170A8F1Q54943618-2BC31C73-EA65-468E-8A29-628247951772
P2860
Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Primary B-CLL resistance to NK ...... d monoclonal antibody therapy.
@en
Primary B-CLL resistance to NK ...... d monoclonal antibody therapy.
@nl
type
label
Primary B-CLL resistance to NK ...... d monoclonal antibody therapy.
@en
Primary B-CLL resistance to NK ...... d monoclonal antibody therapy.
@nl
prefLabel
Primary B-CLL resistance to NK ...... d monoclonal antibody therapy.
@en
Primary B-CLL resistance to NK ...... d monoclonal antibody therapy.
@nl
P2093
P2860
P1476
Primary B-CLL resistance to NK ...... d monoclonal antibody therapy.
@en
P2093
Caroline Veuillen
Daniel Olive
Diane Coso
Florence Orlanducci
Françoise Mallet
Jérôme Rey
Laurent Pouyet
Réda Bouabdallah
Rémy Castellano
Sylvaine Just-Landi
P2860
P2888
P304
P356
10.1007/S10875-011-9624-5
P577
2012-02-09T00:00:00Z
P6179
1015408541